Advances in oral high-efficacy disease-modifying drugs in the treatment of multiple sclerosis in remission
Multiple sclerosis(MS)is an immune-mediated disease characterized by inflammatory demyelinating lesions of the central nervous system.Cognitive impairment is an important contributor to patients'disease burden.Reducing brain volume loss and improving cognition have become important components of the treatment goals of MS in remission and oral high-efficacy disease modifying treatment(DMT)drugs(sphingosine 1 phosphate)are currently commonly used in China as DMT regimens.Through literature review,this article provided an overview of the current status and future outlook of the effi-cacy and adverse events of domestically marketed oral high-efficacy DMT drugs,as well as patient medication monitoring and management.
multiple sclerosisoral high-efficacy disease modifying drugsevidence of efficacyadverse eventsmedica-tion management
NETL
NSTL
万方数据
